Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development and therapeutic impact of HDAC6-selective inhibitors
Sabrina Dallavalle, Claudio Pisano, Franco Zunino
Biochemical Pharmacology (2012) Vol. 84, Iss. 6, pp. 756-765
Closed Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes
Yingxiu Li, Donghee Shin, So Hee Kwon
FEBS Journal (2012) Vol. 280, Iss. 3, pp. 775-793
Open Access | Times Cited: 317
Histone deacetylase 6 in cancer
Ting Li, Chao Zhang, Shafat Hassan, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 279
The Chemical Biology of Ferroptosis in the Central Nervous System
Rajiv R. Ratan
Cell chemical biology (2020) Vol. 27, Iss. 5, pp. 479-498
Open Access | Times Cited: 148
Tubastatin A/ACY-1215 Improves Cognition in Alzheimer's Disease Transgenic Mice1
Ling Zhang, Cui Liu, Jie Wu, et al.
Journal of Alzheimer s Disease (2014) Vol. 41, Iss. 4, pp. 1193-1205
Closed Access | Times Cited: 166
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors
Nicholas J. Porter, Adaickapillai Mahendran, Ronald Breslow, et al.
Proceedings of the National Academy of Sciences (2017) Vol. 114, Iss. 51, pp. 13459-13464
Open Access | Times Cited: 155
Recent advances in the discovery of potent and selective HDAC6 inhibitors
Xiuxiu Wang, Renzhong Wan, Zhao‐Peng Liu
European Journal of Medicinal Chemistry (2017) Vol. 143, pp. 1406-1418
Closed Access | Times Cited: 137
Development of a histone deacetylase 6 inhibitor and its biological effects
Ju‐Hee Lee, Adaickapillai Mahendran, Yuanshan Yao, et al.
Proceedings of the National Academy of Sciences (2013) Vol. 110, Iss. 39, pp. 15704-15709
Open Access | Times Cited: 132
Drugging the HDAC6–HSP90 interplay in malignant cells
Oliver H. Krämer, Siavosh Mahboobi, Andreas Sellmer
Trends in Pharmacological Sciences (2014) Vol. 35, Iss. 10, pp. 501-509
Open Access | Times Cited: 123
Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition
Maj-Linda B. Selenica, Leif Benner, Steven B. Housley, et al.
Alzheimer s Research & Therapy (2014) Vol. 6, Iss. 1
Open Access | Times Cited: 120
The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
Chiara Zagni, Giuseppe Floresta, Giulia Monciino, et al.
Medicinal Research Reviews (2017) Vol. 37, Iss. 6, pp. 1373-1428
Closed Access | Times Cited: 117
Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif
Florence F. Wagner, David E. Olson, Jennifer Gale, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 4, pp. 1772-1776
Closed Access | Times Cited: 112
Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors
Johanna Senger, Jelena Melesina, Martin Marek, et al.
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 4, pp. 1545-1555
Closed Access | Times Cited: 105
Oncogenes induce a vimentin filament collapse mediated by HDAC6 that is linked to cell stiffness
Li-Sophie Zhao Rathje, Niklas Nordgren, Torbjörn Pettersson, et al.
Proceedings of the National Academy of Sciences (2014) Vol. 111, Iss. 4, pp. 1515-1520
Open Access | Times Cited: 103
Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors
Katharina Vögerl, Nghia Ong, Johanna Senger, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 3, pp. 1138-1166
Open Access | Times Cited: 89
Epigenetic Mechanisms in Cerebral Ischemia
Sophie Schweizer, Andreas Meisel, Stefanie Märschenz
Journal of Cerebral Blood Flow & Metabolism (2013) Vol. 33, Iss. 9, pp. 1335-1346
Open Access | Times Cited: 99
Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines
Eugene Guorong Yang, Nurulhuda Mustafa, Eng Chong Tan, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 18, pp. 8233-8262
Closed Access | Times Cited: 85
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease
Sri Nagarjun Batchu, Angela S. Brijmohan, Andrew Advani
Clinical Science (2016) Vol. 130, Iss. 12, pp. 987-1003
Closed Access | Times Cited: 83
Unique functional roles for class I and class II histone deacetylases in central nervous system development and function
Michael J. Morris, Lisa M. Monteggia
International Journal of Developmental Neuroscience (2013) Vol. 31, Iss. 6, pp. 370-381
Open Access | Times Cited: 72
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
Maria Cosenza, Samantha Pozzi
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 8, pp. 2337-2337
Open Access | Times Cited: 72
PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition
Ziyu Meng, L-F Jia, Y‐H. Gan
Oncogene (2015) Vol. 35, Iss. 18, pp. 2333-2344
Open Access | Times Cited: 70
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors
Andreas Sellmer, Hubert Stangl, Mandy Beyer, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 8, pp. 3454-3477
Closed Access | Times Cited: 67
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao, Hang Zhang, Frédéric Lirussi, et al.
Biochemical Pharmacology (2020) Vol. 182, pp. 114224-114224
Open Access | Times Cited: 60
Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70
Ping Gong, Yuetong Wang, Yongkui Jing
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 7, pp. 1601-1601
Open Access | Times Cited: 56
Microtubule associated proteins as targets for anticancer drug development
Sadiya Khwaja, Kapil Kumar, Ranjana Das, et al.
Bioorganic Chemistry (2021) Vol. 116, pp. 105320-105320
Closed Access | Times Cited: 47
Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs
Melissa Cantley, David R. Haynes
Inflammopharmacology (2013) Vol. 21, Iss. 4, pp. 301-307
Closed Access | Times Cited: 67
Page 1 - Next Page

Scroll to top